Contact Us   |   Print Page   |   Sign In   |   Join
News and Press: Member Organization News

Armune BioScience, Inc. Receives State of Florida Clinical Laboratory License

Tuesday, August 9, 2016   (0 Comments)
Posted by: Kate Oesterle
Share |

KALAMAZOO, MI - Armune BioScience, the developer of APIFINY®, the only cancer specific, non-PSA blood testavailable to assess the risk for the presence of prostate cancer, today announced its Ann Arbor laboratory has received a laboratory license from the state of Florida.

“We are excited to enter the Florida market with the recent approval of our laboratory license by the state of Florida,” said David Esposito, President and Chief Executive Officer of Armune BioScience. “With over 7,000 tests ordered since the launch of APIFINY, we anticipate significant demand from the Florida market. Given the current concerns of PSA testing throughout the world, APIFINY is well positioned to offer clinicians additional information in the assessment of prostate cancer risk. In addition, we are confident that APIFINY will help to address our healthcare system’s demand for improved outcomes at lower costs.”

Read full article.

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal